Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Xiaoping Shi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Linezolid, Thrombocytopenia, Anti-Bacterial Agents, Liver Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: the Shanghai Municipal Health Commission Clinical Research Youth Project, the National Natural Science Foundation-Youth Foundation, the Fudan Undergraduate Research Opportunities Program (FDUROP).
Abstract (Originalsprache)
Background
Linezolid is a commonly prescribed antibiotic for multidrug-resistant enterococcal infections in liver transplant recipients (LTRs). However, changes in pharmacokinetics due to fluctuations in liver and renal functions, combined with the increased risk of thrombocytopenia, complicate its clinical use. This study aimed to characterize the exposure-thrombocytopenia risk relationship of linezolid in LTRs, and to identify safe dosing thresholds to promote rational drug use.
Methods
A retrospective analysis was conducted on adult LTRs treated with linezolid at Zhongshan Hospital between January 2019 and May 2022. A population exposure-safety model was developed and used to establish a thrombocytopenia risk threshold and optimize initial dosing strategies through Monte Carlo simulations. An area under the concentration–time curve (AUC) calculator was developed to facilitate individualized dose adjustments.
Results
Exposure-safety analysis revealed that an AUCss,24h threshold of 291.7 mg/L·h was associated with an increased risk of thrombocytopenia. Monte Carlo simulations showed that current covariate-based initial dosing recommendations were suboptimal, highlighting the necessity of therapeutic drug monitoring (TDM) to improve outcomes in LTRs. The online AUC calculator developed in this study offers a practical tool for clinicians to implement timely dose adjustments (https://optimaldose.shinyapps.io/LinezolidAUC/).
Conclusions
This study provides the first comprehensive analysis of linezolid exposure and its relationship to thrombocytopenia risk in LTRs. The findings underscore the importance of AUC-guided dosing and TDM in optimizing treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
- Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Xiaoping Shi, Xiao Zhu
Förderung
- the Shanghai Municipal Health Commission Clinical Research Youth Project
- the National Natural Science Foundation-Youth Foundation
- the Fudan Undergraduate Research Opportunities Program (FDUROP)
- the National Undergraduate Training Program on Innovation and Entrepreneurship
Zitieren
APA
Shi, X., Yang, W., Zhao, F., Lao, D., Xu, Q., Li, X., Lv, Q., He, Q., Xiang, X., Wang, T., & Zhu, X. (2025). Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf147
Vancouver
Shi X, Yang W, Zhao F, Lao D, Xu Q, Li X, et al. Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf147
BibTeX
@article{Shi2025,
author = {Shi, Xiaoping and Yang, Wenyu and Zhao, Fanyu and Lao, Donghui and Xu, Qing and Li, Xiaoyu and Lv, Qianzhou and He, Qingfeng and Xiang, Xiaoqiang and Wang, Ting and Zhu, Xiao},
title = {Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf147}
}
EUVIMED